This new investment comes after the completion in early 2016 of a new CTD2 facility for the handling (development / manufacturing) of oral solid dosage Drug Product manufacturing of Highly Potent & Oncology compounds in its CordenPharma Plankstadt (Germany) facility, along with further expansion of capabilities in handling sterile Oncology Drug Products at CordenPharma Latina (Italy).